efficacy of tirzepatide and Safety in Adults with Obesity or Overweight Published July 21, 2022 N Engl J Med 2022;387:205–216 🔹 Background Obesity and overweight remain major global health problems associated with Tirzepatide for the Maintenance of

Semaglutide 2.4 mg (Wegovy), a once-weekly GLP-1 receptor agonist licensed by the MHRA and recommended by NICE (Technology Appraisal TA875) for use in specific circumstances, demonstrated mean weight loss of approximately 14.9% from baseline at 68 weeks in the STEP 1 phase 3 trial (Wilding JPH et al., N Engl J Med

Each vegan tablet provides 25mg of highly bioavailable zinc bisglycinate, enhanced with copper, selenium, and chromium for optimal absorption and synergistic benefits

Working two pathways at once tends to produce a stronger effect on appetite, blood sugar, and the visceral fat that drives cardiometabolic risk

Patients report better tolerance when they skip the juice aisle entirely and choose whole fruits instead